2012–2019年柳州市肝癌发病与死亡分析

沈丹豫; 周丽芳; 蓝剑; 陈宁钰; 刘芸

doi:10.16462/j.cnki.zhjbkz.2025.05.010

2012–2019年柳州市肝癌发病与死亡分析

doi: 10.16462/j.cnki.zhjbkz.2025.05.010

沈丹豫¹,
周丽芳^{2, 3, ,},
蓝剑³,
陈宁钰³,
刘芸³

1.
桂林医学院公共卫生学院，桂林 541100
2.
广西医科大学第四附属医院办公室，柳州 545005
3.
柳州市疾病预防控制中心慢性非传染病防制所，柳州 545005

基金项目:

国家自然科学基金-地区科学基金 71964003

广西壮族自治区科学技术厅自然科学基金 2019GXNSFAA185040

详细信息

通讯作者:
周丽芳, E-mail: alice06132010@163.com

中图分类号: R735.7;R181
计量
- 文章访问数: 6
- HTML全文浏览量: 3
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2024-09-11
- 修回日期: 2025-01-27
- 网络出版日期: 2025-06-28
- 刊出日期: 2025-05-10

Analysis of the incidence and mortality of liver cancer in Liuzhou City from 2012 to 2019

1.
School of Public Health, Guilin Medical University, Guilin 541100, China
2.
Administrative Office, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou 545005, China
3.
Chronic Diseases Prevention Office, Liuzhou Center for Disease Control and Prevention, Liuzhou 545005, China

Funds:

National Natural Science Foundation-Regional Science Foundation 71964003

Natural Science Fund of Guangxi Zhuang Autonomous Region Science and Technology Department 2019GXNSFAA185040

More Information

Corresponding author: ZHOU Lifang, E-mail: alice06132010@163.com

摘要

摘要: 目的分析2012–2019年柳州市肝癌发病与死亡情况及变化趋势，了解当前柳州市肝癌的防控现状。方法通过广西壮族自治区柳州市肿瘤登记中心获取2012–2019年柳州市居民肝癌发病、死亡和人口资料，计算发病率、死亡率，中国人口标化发病率、死亡率，世界人口标化发病率、死亡率等，利用Joinpoint 5.0.2软件对发病率、死亡率的变化趋势进行分析。结果肝癌发病数共3 844例，发病率为33.99/10万，中国人口标化发病率为34.44/10万，世界人口标化发病率为26.89/10万。肝癌死亡数共3 116例，死亡率为27.55/10万，中国人口标化死亡率为28.01/10万，世界人口标化死亡率为21.76/10万。性别方面，男性发病率和死亡率水平均高于女性；年龄方面，肝癌发病率和死亡率均随年龄的增长而增加，≥85岁年龄组的发病率和死亡率最高；变化趋势方面，2012–2019年肝癌发病率总体呈先增长后下降趋势，中国人口标化发病率由35.53/10万下降至33.01/10万，肝癌死亡率呈缓慢上升趋势，中国人口标化死亡率由28.94/10万上升至30.84/10万，但差异均无统计学意义(均P>0.05)。结论 2012–2019年柳州市居民肝癌发病率呈下降趋势，但发病率和死亡率仍偏高，肝癌的疾病负担较重，应加强肝癌筛查和早诊早治力度，同时利用多种健康宣教活动，提倡健康生活方式，提高居民健康水平。
- 肝癌 /
- 发病率 /
- 死亡率 /
- 变化趋势
Abstract: Objective This study aims to analyze the incidence and mortality rates of liver cancer in Liuzhou City, and to assess the current prevention and control measures. Methods Data on the incidence, mortality, and population statistics related to liver cancer in Liuzhou City were collected. The crude incidence and mortality rates, as well as the age-standardized incidence and mortality rates for both the Chinese and global populations, were calculated. Joinpoint 5.0.2 software was utilized to analyze trends in morbidity and mortality rates. Results A total of 3 844 liver cancer cases were reported, resulting in a incidence rate of 33.99 per 100 000 individuals. The age-standardized incidence rate was 34.44 per 100 000 for the Chinese population and 26.89 per 100 000 for the global population. There were 3 116 liver cancer-related deaths, yielding a crude mortality rate of 27.55 per 100 000. The age-standardized mortality rate was 28.01 per 100 000 for the Chinese population and 21.76 per 100 000 for the global population. In terms of gender, both incidence and mortality rates were higher in males compared to females. Additionally, both rates increased with age, peaking in the ≥85 years age group. From the changing trends, the incidence of liver cancer initially increased and then decreased. The age-standardized incidence rate for the Chinese population declined from 35.53 per 100 000 to 33.01 per 100 000. In contrast, the mortality rate for liver cancer exhibited a gradual upward trend, with the age-standardized mortality rate for the Chinese population rising from 28.94 per 100 000 to 30.84 per 100 000, but there were no significant difference (all P>0.05). Conclusions Although the incidence of liver cancer among residents of Liuzhou shows a downward trend, the morbidity and mortality rates remain high, indicating a significant disease burden. Therefore, it is essential to enhance implement liver cancer screening and early diagnosis and treatment protocols, and promote healthy lifestyle choices through diverse health education initiatives.
- Liver cancer /
- Incidence /
- Mortality /
- Variation tendency

HTML全文

图 1 2012–2019年柳州市居民肝癌发病率变化趋势

Figure 1. Trend of incidence rate of liver cancer in Liuzhou residents, 2012-2019

下载: 全尺寸图片幻灯片

图 2 2012–2019年柳州市居民不同年龄组肝癌发病率变化趋势

Figure 2. Trend of incidence rate of liver cancer in different age groups of Liuzhou residents, 2012-2019

下载: 全尺寸图片幻灯片

图 3 2012–2019年柳州市居民肝癌死亡率的变化趋势

Figure 3. Trend of mortality rate of liver cancer among residents in Liuzhou, 2012 to 2019

下载: 全尺寸图片幻灯片

图 4 2012–2019年柳州市居民不同年龄组肝癌死亡率变化趋势

Figure 4. Trend of mortality rate of liver cancer in different age groups of Liuzhou residents, 2012-2019

下载: 全尺寸图片幻灯片

表 1 2012–2019年柳州市肝癌发病情况

Table 1. Incidence of liver cancer in Liuzhou City, 2012-2019

年份 Year	男性Male			女性Female			合计Total
年份 Year	发病率 Incidence rate/100 000^-1	ASRC/100 000^-1	ASRW/100 000^-1	发病率 Incidence rate/100 000^-1	ASRC/100 000^-1	ASRW/100 000^-1	发病率 Incidence rate/100 000^-1	ASRC/100 000^-1	ASRW/100 000^-1
2012	52.81	56.44	43.41	14.00	14.41	11.25	33.98	35.53	27.43
2013	49.22	53.52	41.54	13.53	13.79	11.30	31.89	33.43	26.29
2014	48.26	52.35	41.64	12.78	12.95	9.49	31.04	32.68	25.59
2015	52.21	57.46	44.68	13.27	13.47	10.03	33.31	35.20	27.16
2016	53.93	59.39	46.43	15.26	15.54	11.78	35.15	37.25	28.93
2017	54.89	56.29	44.01	16.42	15.64	11.93	36.12	36.04	28.06
2018	53.02	54.48	42.53	14.02	13.28	10.35	33.98	33.90	26.52
2019	54.13	53.05	41.71	13.84	12.21	9.71	34.80	33.01	26.00
合计Total	52.61	55.02	43.02	14.25	13.81	10.67	33.99	34.44	26.89
注：ASRC，中国人口标化率；ASRW，世界人口标化率。 Note: ASRC, age-standardized rate by Chinese standard population; ASRW, age-standardized rate by world standard population.

下载: 导出CSV

表 2 2012–2019年柳州市肝癌死亡情况

Table 2. Live cancer mortality in Liuzhou City, 2012-2019

年份 Year	男性Male			女性Female			合计Total
年份 Year	死亡率 Mortality rate/100 000^-1	ASRC/100 000^-1	ASRW/100 000^-1	死亡率 Mortality rate/100 000^-1	ASRC/100 000^-1	ASRW/100 000^-1	死亡率 Mortality rate/100 000^-1	ASRC/100 000^-1	ASRW/100 000^-1
2012	41.57	45.81	35.35	12.11	12.47	9.47	27.27	28.94	22.28
2013	39.64	43.92	33.45	9.79	9.95	7.76	25.15	26.64	20.42
2014	37.19	41.00	31.77	10.16	10.35	7.42	24.06	25.58	19.54
2015	42.94	47.77	38.04	12.58	12.76	9.56	28.20	29.98	23.58
2016	41.45	46.15	36.08	12.04	12.36	9.29	27.17	28.91	22.41
2017	40.98	42.06	32.99	13.23	12.52	9.61	27.44	27.37	21.38
2018	41.47	42.72	33.21	10.77	10.01	7.66	26.49	26.41	20.50
2019	51.44	50.82	39.88	11.81	10.36	7.82	32.43	30.84	24.07
合计Total	42.57	44.90	35.05	11.62	11.23	8.51	27.55	28.01	21.76
注：ASRC，中国人口标化率；ASRW，世界人口标化率。 Note: ASRC, age-standardized rate by Chinese standard population; ASRW, age-standardized rate by world standard population.

下载: 导出CSV

参考文献(10)

[1]	周丽芳. 重大慢性病住院患者直接经济负担研究: 以广西心血管疾病、肺癌及鼻咽癌为例[M]. 南宁: 广西科学技术出版社, 2023: 1-143. Zhou LF. Study on the direct economic burden of inpatients with major chronic diseases: cardiovascular disease, lung cancer, and nasopharyngeal cancer in Guangxi[M]. Nangning: Guangxi Science and Technology Publishing House, 2023: 1-143.
[2]	周子寒, 李秋林, 余家华, 等. 2018年广西恶性肿瘤流行情况及疾病负担分析[J]. 中国癌症防治杂志, 2023, 15(2): 181-189. DOI: 10.3969/j.issn.1674-5671.2023.02.11. Zhou ZH, Li QL, Yu JH, et al. Analysis of the epidemiological characteristics of malignant tumors and disease burden in Guangxi, 2018[J]. Chin J Oncol Prev Treat, 2023, 15(2): 181-189. DOI: 10.3969/j.issn.1674-5671.2023.02.11.
[3]	周子寒, 李秋林, 余家华, 等. 2019年广西恶性肿瘤流行情况及疾病负担分析[J]. 中国癌症防治杂志, 2024, 16(1): 66-75. DOI: 10.3969/j.issn.1674-5671.2024.01.11. Zhou ZH, Li QL, Yu JH, et al. Analysis of the epidemiological characteristics and disease burden of malignant tumors in Guangxi, 2019[J]. Chin J of Oncol Prev Treat, 2024, 16(1): 66-75. DOI: 10.3969/j.issn.1674-5671.2024.01.11.
[4]	Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606. DOI: 10.1016/j.jhep.2022.08.021.
[5]	韩亚蓉, 韩颖颖, 蔡波, 等. 2013–2017年江苏省南通市肝癌空间聚集性研究[J]. 中国肿瘤, 2024, 33(1): 68-73. DOI: 10.11735/j.issn.1004-0242.2024.01.A009. Han YR, Han YY, Cai B, et al. Spatial aggregation distribution of liver cancer in Nantong of Jiangsu, 2013-2017[J]. China Cancer, 2024, 33(1): 68-73. DOI: 10.11735/j.issn.1004-0242.2024.01.A009.
[6]	刘茵, 陈琼, 张璐瑶, 等. 2017年河南省肝癌流行现状及2010-2017年趋势分析[J]. 中国肿瘤, 2022, 31(5): 335-340. DOI: 10.11735/j.issn.1004-0242.2022.05.A003. Liu Y, Chen Q, Zhang LY, et al. Incidence and mortality of liver cancer in 2017 and itstrend from 2010 to 2017 in Henan Province[J]. China Cancer, 2022, 31(5): 335-340. DOI: 10.11735/j.issn.1004-0242.2022.05.A003.
[7]	欧孟言, 周弘烨, 陈丹琪, 等. 2013–2017年广东省肿瘤登记地区老年人恶性肿瘤流行特征及趋势[J]. 中国肿瘤, 2023, 32(5): 348-359. DOI: 10.11735/j.issn.1004-0242.2023.05.A004. Ou MY, Zhou HY, Chen DQ, et al. Cancer incidence, mortality and trends among elderlyin cancer registration areas of Guangdong Province from 2013 to 2017[J]. China Cancer, 2023, 32(5): 348-359. DOI: 10.11735/j.issn.1004-0242.2023.05.A004.
[8]	Cao M, Fan J, Lu L, et al. Long term outcome of prevention of liver cancer by hepatitis B vaccine: Results from an RCT with 37 years[J]. Cancer Lett, 2022, 536: 215652. DOI: 10.1016/j.canlet.2022.215652.
[9]	陈建国, 张永辉, 陆建华, 等. 中国肝癌预防与筛检工作实践及防控挑战[J]. 中国肿瘤, 2023, 32(11): 836-847. DOI: 10.11735/j.issn.1004-0242.2023.11.A005. Chen JG, Zhang YH, Lu JH, et al. Liver cancer prevention and screening in China: Practices and challenges[J]. China Cancer, 2023, 32(11): 836-847. DOI: 10.11735/j.issn.1004-0242.2023.11.A005.
[10]	Zhong QQ, Qin ZS, Wang XW, et al. Healthy sleep pattern reduce the risk of cardiovascular disease: a 10-year prospective cohort study[J]. Sleep Med, 2023, 105: 53-60. DOI: 10.1016/j.sleep.2023.03.003.